Shares of Caribou Biosciences Inc.
CRBU,
tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome editing, said it would grant the underwriters a 30-day option to buy up to an extra $15 million in shares at the public offering price. BofA Securities, Leerink Partners, Evercore ISI, and RBC Capital Markets are acting as the offering’s book-running managers. The company also reported positive clinical data from the dose escalation portion of a Phase 1 trial for a cell therapy being tested in patients with non-Hodgkin lymphoma.
